ClinicalTrials.gg
Not yet recruitingNCT07835932Updated Sep 23, 2026

Randomised Controlled Trial of Fluorescent Urography Using Intravenous Methylene Blue Compared to White Light Alone in Left-sided Colorectal Surgery

A Phase 4 interventional study of Intravenous Methylene blue and Fluorescence Imaging Device for Methylene Blue in Colorectal Surgery and Ureter, sponsored by Chinese University of Hong Kong. Not yet recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Chinese University of Hong Kong · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will see if a blue dye (methylene blue) given into a vein, together with a special camera light, helps surgeons find the left ureter (the tube from the kidney to the bladder) faster during left-sided bowel surgery. Adults having open, laparoscopic, or robotic left-sided colorectal surgery will be randomly assigned to either the blue dye with special light or standard white light alone. The main question is whether the blue dye method finds the ureter more quickly, which could make the operation safer.

Read the detailed description

This randomised controlled trial will test whether intravenous methylene blue, viewed with a special fluorescence camera, helps surgeons identify the left ureter (the tube that carries urine from the kidney to the bladder) more quickly during left-sided colorectal (bowel) surgery. Ureter injury is a rare but serious complication, and in some patients the ureter is hard to see under standard white light. Adults having open, laparoscopic, or robotic left-sided colorectal surgery at Prince of Wales Hospital (Hong Kong) will be screened; if the left ureter cannot be clearly seen before dissection, they will be randomly assigned to either fluorescence imaging with methylene blue or standard white-light vision alone.

The main outcome is the time from starting dissection to first seeing the left ureter. The study will also record how often the ureter is seen at set time points, operating times, surgeon-rated ease and confidence, any changes to the surgical plan, complications, and ureteric injuries. The goal is to find out whether the fluorescence method can make ureter identification faster and easier, potentially improving safety without needing invasive preoperative ureteric stents.

02

Conditions studied

  • Colorectal Surgery
  • Ureter

Keywords

  • Methylene Blue
  • Fluorescence imaging
  • Ureter identification
  • Colorectal surgery
  • Image-guided surgery
03

In context

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,457 studies on the registry; 477 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged ≥18 years
  • Scheduled to undergo open, laparoscopic or robotic left-sided colorectal surgery, including left colectomy, high anterior resection, low anterior resection, abdominoperineal resection, subtotal colectomy and total colectomy.

Exclusion criteria

Exclusion Criteria:

  • Unable to understand the aims and objectives of this study and unable to give consent for participation
  • Known allergy to methylene blue
  • Pregnant
  • Taking selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, or tricyclic antidepressants (risk of serotonin syndrome)
  • Significant renal or hepatic impairment
  • Presence of renal or ureteric obstruction
  • History of G6PD deficiency (risk of hemolytic anemia)
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Fluorescence Imaging with Intravenous Methylene Blue

    Fluorescence Imaging with Intravenous Methylene Blue

    Drug: Intravenous Methylene blue · Device: Fluorescence Imaging Device for Methylene Blue

  • No intervention
    White Light Visualisation Alone

    White Light Visualisation Alone

Interventions

  • DrugMethylene BlueStudies of Methylene BlueMethylene Blue pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravenous methylene blue 0.5-1.0 mg/kg administered intraoperatively for fluorescence ureter identification.

  • DeviceFluorescence Imaging Device for Methylene Blue

    Modified Stryker 1688 Fluorescence Laparoscopic System with additional filter

06

What researchers measure

Primary outcomes

  1. Time to identification of the left ureter

    Time (in minutes) from peritoneal incision to first visualisation of the left ureter during left-sided colorectal surgery.

    Time frame: Intraoperative, from peritoneal incision until the ureter is first seen

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2026
First posted
Sep 23, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Oct 1, 2028
CompletionEst.
Oct 1, 2029
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07835932
Responsible party
Trevor Yeung (Assistant Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Sep 23, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Oct 1, 2028 (estimated)
Completion
Oct 1, 2029 (estimated)
Last update
Sep 23, 2026

Study contacts

Trevor Yeung, MA, MBBChir, DPhil, FRCS
Contact
uretertrial@gmail.com
+852 3505 1495

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methylene Blue

Start the discussion